Goodrx Holdings (GDRX) revenue breakdown
By product, Prescription transactions revenue is the largest at 68% of fiscal 2025 revenue; Pharma manufacturer solutions revenue grew fastest, 49% a year over 5 years.
Revenue by product
Fiscal years, as Goodrx Holdings reports them in its 10-K filings; fiscal 2025 total $797M.
| Products | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|
| Prescription transactions revenue | $243M | $365M | $488M | $593M | $551M | $551M | $578M | $544M | 68% |
| Pharma manufacturer solutions revenue | — | — | $20M | $73M | $99M | $85M | $107M | $151M | 19% |
| Subscription revenue | — | $13M | $29M | $60M | $96M | $94M | $87M | $84M | 11% |
| Other revenue | $7M | $11M | $13M | $19M | $20M | $20M | $21M | $18M | 2% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for GDRX.
Open GDRX in InvestinglyQuestions
Where does Goodrx Holdings make its money?
In fiscal 2025, by product: Prescription transactions revenue $544M, Pharma manufacturer solutions revenue $151M, Subscription revenue $84M, Other revenue $18M.
From Goodrx Holdings's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.